用于早期识别颅内转移性疾病患者的临床生物标志物
Clinical Biomarkers for Early Identification of Patients with Intracranial Metastatic Disease.
作者信息
Gaebe Karolina, Li Alyssa Y, Das Sunit
机构信息
Institute of Medical Science, Faculty of Medicine, University of Toronto, 1 King's College Circle, Toronto, ON M5S 3K1, Canada.
Division of Neurosurgery, St. Michael's Hospital, University of Toronto, 30 Bond Street, Toronto, ON M5B 1W8, Canada.
出版信息
Cancers (Basel). 2021 Nov 27;13(23):5973. doi: 10.3390/cancers13235973.
Abstract
Nearly 30% of patients with cancer will develop intracranial metastatic disease (IMD), and more than half of these patients will die within a few months following their diagnosis. In light of the profound effect of IMD on survival and quality of life, there is significant interest in identifying biomarkers that could facilitate the early detection of IMD or identify patients with cancer who are at high IMD risk. In this review, we will highlight early efforts to identify biomarkers of IMD and consider avenues for future investigation.
摘要
近30%的癌症患者会发生颅内转移性疾病（IMD），其中超过一半的患者在确诊后的几个月内死亡。鉴于IMD对生存和生活质量的深远影响，人们对识别能够促进IMD早期检测或识别高IMD风险癌症患者的生物标志物有着浓厚兴趣。在这篇综述中，我们将重点介绍识别IMD生物标志物的早期努力，并探讨未来的研究途径。
相似文献
1
Clinical Biomarkers for Early Identification of Patients with Intracranial Metastatic Disease.
Cancers (Basel). 2021 Nov 27;13(23):5973. doi: 10.3390/cancers13235973.
2
Incidence and real-world burden of brain metastases from solid tumors and hematologic malignancies in Ontario: a population-based study.
Neurooncol Adv. 2020 Dec 22;3(1):vdaa178. doi: 10.1093/noajnl/vdaa178. eCollection 2021 Jan-Dec.
3
Intracranial Metastatic Disease: Present Challenges, Future Opportunities.
Front Oncol. 2022 Mar 7;12:855182. doi: 10.3389/fonc.2022.855182. eCollection 2022.
4
The Impact of Targeted Therapy on Intracranial Metastatic Disease Incidence and Survival.
Front Oncol. 2019 Aug 23;9:797. doi: 10.3389/fonc.2019.00797. eCollection 2019.
5
A systematic review of evidence on malignant spinal metastases: natural history and technologies for identifying patients at high risk of vertebral fracture and spinal cord compression.
Health Technol Assess. 2013 Sep;17(42):1-274. doi: 10.3310/hta17420.
6
Metastatic diseases of the central nervous system - neuropathologic aspects.
Handb Clin Neurol. 2018;149:67-73. doi: 10.1016/B978-0-12-811161-1.00005-0.
7
Dual- versus single-agent HER2 inhibition and incidence of intracranial metastatic disease: a systematic review and meta-analysis.
NPJ Breast Cancer. 2021 Feb 18;7(1):17. doi: 10.1038/s41523-021-00220-0.
8
Incidence of seizure in adult patients with intracranial metastatic disease.
J Neurooncol. 2017 Feb;131(3):619-624. doi: 10.1007/s11060-016-2335-2. Epub 2016 Nov 22.
9
Single-agent interleukin-2 in the treatment of metastatic melanoma.
Curr Oncol. 2007 Feb;14(1):21-6. doi: 10.3747/co.2007.97.
10
Overview of resistance to systemic therapy in patients with breast cancer.
Adv Exp Med Biol. 2007;608:1-22. doi: 10.1007/978-0-387-74039-3_1.
引用本文的文献
1
Thinking (Metastasis) outside the (Primary Tumor) Box.
Cancers (Basel). 2023 Nov 7;15(22):5315. doi: 10.3390/cancers15225315.
2
Prediction of ROS1 and TRKA/B/C occupancy in plasma and cerebrospinal fluid for entrectinib alone and in DDIs using physiologically based pharmacokinetic (PBPK) modeling approach.
Cancer Chemother Pharmacol. 2024 Feb;93(2):107-119. doi: 10.1007/s00280-023-04598-5. Epub 2023 Oct 14.
3
Prediction of occult tumor progression via platelet RNAs in a mouse melanoma model: a potential new platform for early detection of cancer.
J Transl Med. 2022 Feb 5;20(1):71. doi: 10.1186/s12967-022-03268-z.
本文引用的文献
1
CD74 and CD44 Expression on CTCs in Cancer Patients with Brain Metastasis.
Int J Mol Sci. 2021 Jun 29;22(13):6993. doi: 10.3390/ijms22136993.
2
Serum glial fibrillary acidic protein is a predictor of brain metastases in patients with metastatic breast cancer.
Int J Cancer. 2021 Oct 15;149(8):1605-1618. doi: 10.1002/ijc.33724. Epub 2021 Jul 19.
3
Assessing the Association of Targeted Therapy and Intracranial Metastatic Disease.
JAMA Oncol. 2021 Aug 1;7(8):1220-1224. doi: 10.1001/jamaoncol.2021.1600.
4
ctDNA-Based Liquid Biopsy of Cerebrospinal Fluid in Brain Cancer.
Cancers (Basel). 2021 Apr 21;13(9):1989. doi: 10.3390/cancers13091989.
5
Prospective Assessment of the Association Between Circulating Tumor Cells and Control of Brain Disease After Focal Radiation Therapy of Breast Cancer Brain Metastases.
Adv Radiat Oncol. 2021 Feb 16;6(2):100673. doi: 10.1016/j.adro.2021.100673. eCollection 2021 Mar-Apr.
6
Incidence and real-world burden of brain metastases from solid tumors and hematologic malignancies in Ontario: a population-based study.
Neurooncol Adv. 2020 Dec 22;3(1):vdaa178. doi: 10.1093/noajnl/vdaa178. eCollection 2021 Jan-Dec.
7
MRI radiomic signature predicts intracranial progression-free survival in patients with brain metastases of ALK-positive non-small cell lung cancer.
Transl Lung Cancer Res. 2021 Jan;10(1):368-380. doi: 10.21037/tlcr-20-361.
8
The Biological Meaning of Radiomic Features.
Radiology. 2021 Mar;298(3):505-516. doi: 10.1148/radiol.2021202553. Epub 2021 Jan 5.
9
Serum CD73 is a prognostic factor in patients with metastatic melanoma and is associated with response to anti-PD-1 therapy.
J Immunother Cancer. 2020 Dec;8(2). doi: 10.1136/jitc-2020-001689.
10
Neurofilament Light Chain as A Biomarker for Brain Metastases.
Cancers (Basel). 2020 Oct 2;12(10):2852. doi: 10.3390/cancers12102852.
Zotero 插件